论文部分内容阅读
目的:观察常规加劳拉西泮治疗冠心病合并焦虑抑郁的疗效。方法:选择冠心病合并焦虑抑郁60例,随机分为常规治疗组(对照组)和常规加劳拉西泮组(观察组)各30例,分别采用汉密尔顿焦虑量表(HAMA)在治疗前后进行评测,观察冠心病及焦虑抑郁状态缓解情况。结果:观察组治疗后HAMA评分较对照组显著下降,心绞痛发作次数减少,焦虑抑郁症状减轻。结论:常规加劳拉西泮治疗冠心病合并焦虑抑郁安全有效,效果更好。
Objective: To observe the curative effect of conventional plus lolazepam on patients with coronary heart disease and anxiety and depression. Methods: Sixty CHD patients with anxiety and depression were randomly divided into routine treatment group (control group) and conventional plus lolazepam group (observation group), 30 patients were treated with Hamilton Anxiety Scale (HAMA) before and after treatment Evaluation, observation of coronary heart disease and anxiety and depression relief. Results: The HAMA score of the observation group decreased significantly compared with that of the control group, the number of angina attacks decreased and the symptoms of anxiety and depression alleviated. Conclusion: Conventional plus lolazepam is safe and effective in treating coronary heart disease with anxiety and depression, and the effect is better.